

Joanna Gã³ra-Tybor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5471736/publications.pdf>

Version: 2024-02-01

71
papers

1,479
citations

361296

20
h-index

315616

38
g-index

77
all docs

77
docs citations

77
times ranked

1651
citing authors

#	ARTICLE	IF	CITATIONS
19	Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. <i>Mediators of Inflammation</i> , 2003, 12, 167-171.	1.4	21
20	Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from primary B-cell chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 2005, 153, 833-837.	1.4	21
21	Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 62-67.	0.6	20
22	Poor prognosis of <sc>H</sc>odgkin variant of <sc>R</sc>ichter transformation in chronic lymphocytic leukemia treated with cladribine. <i>British Journal of Haematology</i> , 2012, 158, 286-288.	1.2	20
23	Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2020, 10, 89.	2.8	20
24	The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. <i>British Journal of Haematology</i> , 1998, 103, 716-720.	1.2	13
25	Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. <i>European Journal of Haematology</i> , 2002, 69, 27-36.	1.1	13
26	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. <i>Leukemia and Lymphoma</i> , 2004, 45, 1261-1267.	0.6	13
27	Emerging Therapies in Chronic Myeloid Leukemia. <i>Current Cancer Drug Targets</i> , 2012, 12, 458-470.	0.8	12
28	Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 283-295.	0.2	12
29	Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. <i>Blood Advances</i> , 2022, 6, 5171-5183.	2.5	12
30	Coexistence of Chronic Lymphocytic Leukemia and Essential Thrombocythemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1425-1431.	0.6	11
31	The interaction of 2-chlorodeoxy adenosine (2-CDA) and interferon $\hat{\pm}$ (IFN- $\hat{\pm}$) on normal and myeloid leukemia hematopoiesis in vitro. <i>Leukemia Research</i> , 1994, 18, 275-281.	0.4	10
32	Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1092-1101.	0.6	10
33	Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 139-143.	0.6	10
34	Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2009, 50, 2096-2097.	0.6	8
35	Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?. <i>International Journal of Cancer</i> , 2021, 148, 1616-1624.	2.3	7
36	Fulminant 2-Chlorodeoxyadenosine-Related Peripheral Neuropathy in a Patient with Paraneoplastic Neurological Syndrome Associated with Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 21, 343-346.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1351-1353.	0.6	6
38	Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.. <i>Blood</i> , 2006, 108, 2485-2485.	0.6	6
39	Influence of cladribine alone and in combinaton with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1042-1044.	0.6	5
40	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 606-610.	0.6	5
41	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e283-e285.	0.2	5
42	Nanoparticles – a Novel Approach to Chronic Lymphocytic Leukemia Treatment?. <i>Blood</i> , 2012, 120, 4601-4601.	0.6	5
43	Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis. <i>European Journal of Haematology</i> , 2021, 107, 129-136.	1.1	4
44	Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.. <i>Blood</i> , 2004, 104, 337-337.	0.6	4
45	The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 405-415.	0.2	4
46	Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil – follow-up of <sc>PALG</sc>-based <sc>CLL</sc> randomized trials. <i>European Journal of Haematology</i> , 2013, 91, 1-9.	1.1	3
47	Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.. <i>Blood</i> , 2004, 104, 3478-3478.	0.6	3
48	Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib. <i>Blood</i> , 2013, 122, 1491-1491.	0.6	3
49	A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor- β and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice. <i>Mediators of Inflammation</i> , 1994, 3, 411-414.	1.4	2
50	The Influence of 2-Chlorodeoxyadenosine (2-CdA) Alone and in Combination with Cyclophosphamide or Methotrexate on Normal and Leukemic Hematopoiesis. <i>Advances in Experimental Medicine and Biology</i> , 1995, 370, 129-130.	0.8	2
51	Współistnienie dyskrazji komórek plazmatycznych i zespołu mielodysplastycznego – opisy przypadków i przegląd piśmiennictwa. <i>Hematologia</i> , 2017, 8, 144-151.	0.0	2
52	The influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor- β or its mutein on murine leukaemias L1210 and P388. <i>Mediators of Inflammation</i> , 1995, 4, 205-208.	1.4	1
53	Zalecenia dotyczące oceny schorzeń, współistniejących u chorych na przewlekłą, białaczkę szpikową, w procesie wyboru inhibitora kinaz tyrozynowych. <i>Acta Haematologica Polonica</i> , 2016, 47, 184-196.	0.1	1
54	A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report. <i>Blood</i> , 2020, 136, 40-41.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).. Blood, 2008, 112, 2103-2103.	0.6	1
56	Limfocytarne zapalenie opon mózgowo-rdzeniowych w przebiegu dokonańowego leczenia liposomalną cytarabiną... u chorego na ostrą białaczkę limfoblastyczną... Hematologia, 2017, 8, 228-233.	0.0	1
57	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study.. Blood, 2006, 108, 2826-2826.	0.6	1
58	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry. Blood, 2016, 128, 1909-1909.	0.6	1
59	Dasatinib in the Treatment of Chronic Myeloid Leukemia. Current Signal Transduction Therapy, 2011, 6, 99-105.	0.3	0
60	The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.. Blood, 2004, 104, 4819-4819.	0.6	0
61	Circulating Endothelial Cells as Noninvasive Marker of Angiogenesis in Patients with Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 1124-1124.	0.6	0
62	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 4467-4467.	0.6	0
63	Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML). Blood, 2014, 124, 5222-5222.	0.6	0
64	Nowotwory mieloproliferacyjne i zespoły mielodysplastyczne – postępy w diagnostyce i terapii. Hematologia, 2015, 6, 70-76.	0.0	0
65	Znaczenie prognostyczne minimalnej choroby resztkowej ocenianej metodą cytometrii przepływowej w ostrej białaczce szpikowej. Hematologia, 2016, 7, 97-107.	0.0	0
66	Ocena stanu odżywienia pacjentów z nowotworami układu krwiotwórczego i chłonnego za pomocą skali PG-SGA. Hematologia, 2017, 8, 105-112.	0.0	0
67	Przeszczepienie allogenicznego krwiotwórczych komórek macierzystych w leczeniu chorych na mielofibrozę. Hematologia, 2017, 8, 132-143.	0.0	0
68	Miejsce ruxsolitynibu w leczeniu chorych na mielofibrozę. Hematologia, 2018, 9, 90-99.	0.0	0
69	Leki wpływające na mechanizmy epigenetyczne w ostrej białaczce szpikowej. Hematologia, 2018, 9, 110-122.	0.0	0
70	Zaburzenia mechanizmów epigenetycznych w ostrej białaczce szpikowej. Hematologia, 2018, 9, 100-109.	0.0	0
71	Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology, and Polish Adult Leukemia Study Group. 2020. Acta Haematologica Polonica. 2020. 51. 60-72.	0.1	0